WuXi Biologics (Cayman) Inc.
WXIBF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $96,586,005 | $64,653,826 | $43,169,130 | $118,107,495 |
| - Cash | $8,439,058 | $8,279,182 | $9,153,528 | $9,669,839 |
| + Debt | $5,107,062 | $4,939,849 | $4,567,208 | $4,561,359 |
| Enterprise Value | $93,254,009 | $61,314,493 | $38,582,810 | $112,999,015 |
| Revenue | $9,953,216 | $10,101,157 | $8,574,214 | $8,542,209 |
| % Growth | -1.5% | 17.8% | 0.4% | – |
| Gross Profit | $4,252,852 | $4,300,869 | $3,349,951 | $3,267,267 |
| % Margin | 42.7% | 42.6% | 39.1% | 38.2% |
| EBITDA | $3,449,063 | $3,956,042 | $2,472,997 | $2,128,112 |
| % Margin | 34.7% | 39.2% | 28.8% | 24.9% |
| Net Income | $2,339,266 | $1,857,001 | $1,499,080 | $1,133,054 |
| % Margin | 23.5% | 18.4% | 17.5% | 13.3% |
| EPS Diluted | 0.55 | 0.43 | 0.35 | 0.26 |
| % Growth | 27.9% | 22.9% | 34.6% | – |
| Operating Cash Flow | $1,806,754 | $3,915,138 | $1,302,119 | $2,333,856 |
| Capital Expenditures | -$1,900,414 | -$2,062,237 | -$1,867,384 | -$2,115,257 |
| Free Cash Flow | -$93,660 | $1,852,901 | -$565,265 | $218,599 |